Annual CFF
-$257.00 K
-$42.60 M-100.61%
30 September 2022
Summary:
NeuBase Therapeutics annual cash flow from financing activities is currently -$257.00 thousand, with the most recent change of -$42.60 million (-100.61%) on 30 September 2022. During the last 3 years, it has fallen by -$42.60 million (-100.61%).NBSE Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$174.50 K
-$4.72 M-103.84%
30 September 2023
Summary:
NeuBase Therapeutics quarterly cash flow from financing activities is currently -$174.50 thousand, with the most recent change of -$4.72 million (-103.84%) on 30 September 2023.NBSE Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$4.25 M
-$147.20 K-3.34%
30 September 2023
Summary:
NeuBase Therapeutics TTM cash flow from financing activities is currently $4.25 million, with the most recent change of -$147.20 thousand (-3.34%) on 30 September 2023.NBSE TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBSE Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -100.6% | -12.4% | -90.0% |
| 5 y5 years | -101.9% | -101.3% | -68.7% |
NBSE Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | -100.6% | -100.4% | -90.9% |
NeuBase Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2023 | - | -$174.50 K(-103.8%) | $4.25 M(-3.3%) |
| June 2023 | - | $4.55 M(-5242.6%) | $4.40 M(-2660.7%) |
| Mar 2023 | - | -$88.40 K(+209.1%) | -$171.90 K(+55.4%) |
| Dec 2022 | - | -$28.60 K(+4.8%) | -$110.60 K(-57.0%) |
| Sept 2022 | -$257.00 K(-100.6%) | -$27.30 K(-1.1%) | -$257.00 K(-33.2%) |
| June 2022 | - | -$27.60 K(+1.8%) | -$385.00 K(-100.9%) |
| Mar 2022 | - | -$27.10 K(-84.5%) | $42.16 M(-0.1%) |
| Dec 2021 | - | -$175.00 K(+12.7%) | $42.19 M(-0.4%) |
| Sept 2021 | $42.34 M(+27.9%) | -$155.30 K(-100.4%) | $42.34 M(-0.3%) |
| June 2021 | - | $42.52 M(>+9900.0%) | $42.48 M(+28.0%) |
| Mar 2021 | - | $0.00(-100.0%) | $33.20 M(+0.1%) |
| Dec 2020 | - | -$26.10 K(+141.7%) | $33.15 M(+0.1%) |
| Sept 2020 | $33.11 M(+143.5%) | -$10.80 K(-100.0%) | $33.11 M(-29.2%) |
| June 2020 | - | $33.24 M(<-9900.0%) | $46.78 M(+245.4%) |
| Mar 2020 | - | -$49.50 K(-32.6%) | $13.55 M(-0.4%) |
| Dec 2019 | - | -$73.40 K(-100.5%) | $13.59 M(-0.0%) |
| Sept 2019 | $13.60 M(<-9900.0%) | $13.67 M(>+9900.0%) | $13.60 M(-7590.4%) |
| June 2019 | - | $0.00(0.0%) | -$181.50 K(-37.0%) |
| Mar 2019 | - | $0.00(-100.0%) | -$287.90 K(+3.5%) |
| Dec 2018 | - | -$73.20 K(-32.4%) | -$278.10 K(+222.2%) |
| Sept 2018 | -$86.30 K(-100.4%) | -$108.30 K(+1.8%) | -$86.30 K(-744.0%) |
| June 2018 | - | -$106.40 K(-1185.7%) | $13.40 K(-99.9%) |
| Mar 2018 | - | $9800.00(-91.7%) | $12.71 M(+0.1%) |
| Dec 2017 | - | $118.60 K(-1479.1%) | $12.70 M(-34.7%) |
| Sept 2017 | $19.46 M(<-9900.0%) | -$8600.00(-100.1%) | $19.46 M(+0.2%) |
| June 2017 | - | $12.59 M(>+9900.0%) | $19.42 M(+187.2%) |
| Mar 2017 | - | $0.00(-100.0%) | $6.76 M(0.0%) |
| Dec 2016 | - | $6.88 M(<-9900.0%) | $6.76 M(-4604.9%) |
| Sept 2016 | -$150.00 K(-100.6%) | -$43.20 K(-40.3%) | -$150.10 K(-15.7%) |
| June 2016 | - | -$72.40 K(<-9900.0%) | -$178.10 K(+1.4%) |
| Mar 2016 | - | $0.00(-100.0%) | -$175.70 K(-100.7%) |
| Dec 2015 | - | -$34.50 K(-51.5%) | $26.46 M(+0.0%) |
| Sept 2015 | $26.45 M(+55.9%) | -$71.20 K(+1.7%) | $26.45 M(-0.0%) |
| June 2015 | - | -$70.00 K(-100.3%) | $26.46 M(-39.0%) |
| Mar 2015 | - | $26.64 M(<-9900.0%) | $43.38 M(+159.1%) |
| Dec 2014 | - | -$40.90 K(-37.1%) | $16.75 M(-1.3%) |
| Sept 2014 | $16.97 M | -$65.00 K(-100.4%) | $16.97 M(-0.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2014 | - | $16.85 M(>+9900.0%) | $17.04 M(+227.8%) |
| Mar 2014 | - | $800.00(-99.6%) | $5.20 M(-1.4%) |
| Dec 2013 | - | $186.00 K(<-9900.0%) | $5.27 M(+1.7%) |
| Sept 2013 | $5.18 M(+31.1%) | -$1300.00(-100.0%) | $5.18 M(-24.8%) |
| June 2013 | - | $5.01 M(+6783.7%) | $6.89 M(+131.8%) |
| Mar 2013 | - | $72.80 K(-25.2%) | $2.97 M(-0.9%) |
| Dec 2012 | - | $97.30 K(-94.3%) | $3.00 M(-24.1%) |
| Sept 2012 | $3.95 M(+302.5%) | $1.71 M(+55.9%) | $3.95 M(+76.1%) |
| June 2012 | - | $1.09 M(+1013.6%) | $2.24 M(+95.6%) |
| Mar 2012 | - | $98.30 K(-90.6%) | $1.15 M(-23.5%) |
| Dec 2011 | - | $1.05 M(>+9900.0%) | $1.50 M(+52.7%) |
| Sept 2011 | $981.40 K(+57.4%) | $0.00(-100.0%) | $981.30 K(-0.3%) |
| June 2011 | - | -$1700.00(-100.4%) | $984.50 K(+0.6%) |
| Mar 2011 | - | $449.80 K(-15.6%) | $978.20 K(+18.9%) |
| Dec 2010 | - | $533.20 K(>+9900.0%) | $822.70 K(+31.9%) |
| Sept 2010 | $623.60 K(-35.4%) | $3200.00(-140.0%) | $623.60 K(+1.7%) |
| June 2010 | - | -$8000.00(-102.7%) | $612.90 K(-58.2%) |
| Mar 2010 | - | $294.30 K(-11.9%) | $1.47 M(+13.0%) |
| Dec 2009 | - | $334.10 K(-4554.7%) | $1.30 M(+34.6%) |
| Sept 2009 | $965.00 K(>+9900.0%) | -$7500.00(-100.9%) | $965.00 K(-0.8%) |
| June 2009 | - | $847.00 K(+574.9%) | $972.50 K(+674.9%) |
| Mar 2009 | - | $125.50 K(>+9900.0%) | $125.50 K(>+9900.0%) |
| Dec 2008 | - | $0.00(0.0%) | $0.00(0.0%) |
| Sept 2008 | $0.00(-100.0%) | $0.00(0.0%) | $0.00(0.0%) |
| June 2008 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2008 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 2007 | - | $0.00(-100.0%) | $0.00(-100.0%) |
| Sept 2007 | $5.91 M(<-9900.0%) | - | - |
| June 2006 | - | $4800.00(-200.0%) | -$26.90 K(+2.7%) |
| Mar 2006 | - | -$4800.00(-82.2%) | -$26.20 K(-2.6%) |
| Dec 2005 | -$26.90 K(+96.4%) | -$26.90 K(-589.1%) | -$26.90 K(+228.0%) |
| June 2005 | - | $5500.00(-200.0%) | -$8200.00(-48.8%) |
| Mar 2005 | - | -$5500.00(+34.1%) | -$16.00 K(+16.8%) |
| Dec 2004 | -$13.70 K(-102.2%) | -$4100.00(0.0%) | -$13.70 K(+42.7%) |
| Sept 2004 | - | -$4100.00(+78.3%) | -$9600.00(+74.5%) |
| June 2004 | - | -$2300.00(-28.1%) | -$5500.00(+71.9%) |
| Mar 2004 | - | -$3200.00 | -$3200.00 |
| Dec 2003 | $630.30 K | - | - |
FAQ
- What is NeuBase Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for NeuBase Therapeutics?
- What is NeuBase Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for NeuBase Therapeutics?
- What is NeuBase Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for NeuBase Therapeutics?
What is NeuBase Therapeutics annual cash flow from financing activities?
The current annual CFF of NBSE is -$257.00 K
What is the all time high annual CFF for NeuBase Therapeutics?
NeuBase Therapeutics all-time high annual cash flow from financing activities is $42.34 M
What is NeuBase Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of NBSE is -$174.50 K
What is the all time high quarterly CFF for NeuBase Therapeutics?
NeuBase Therapeutics all-time high quarterly cash flow from financing activities is $42.52 M
What is NeuBase Therapeutics TTM cash flow from financing activities?
The current TTM CFF of NBSE is $4.25 M
What is the all time high TTM CFF for NeuBase Therapeutics?
NeuBase Therapeutics all-time high TTM cash flow from financing activities is $46.78 M